Brokerages Set Stryker Co. (NYSE:SYK) PT at $427.30

Stryker Co. (NYSE:SYK - Get Free Report) has earned an average rating of "Moderate Buy" from the nineteen brokerages that are covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $427.30.

Several equities analysts have recently issued reports on the company. Needham & Company LLC reissued a "buy" rating and set a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Barclays upped their price target on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. The Goldman Sachs Group set a $422.00 price target on Stryker in a research note on Tuesday, March 4th. BTIG Research set a $403.00 target price on Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. Finally, Evercore ISI cut their target price on Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.20% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. J. W. Coons Advisors LLC raised its stake in shares of Stryker by 0.7% in the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after buying an additional 26 shares during the period. Mascoma Wealth Management LLC raised its stake in shares of Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after buying an additional 27 shares during the period. Opal Wealth Advisors LLC raised its stake in shares of Stryker by 1.6% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after buying an additional 28 shares during the period. Lindbrook Capital LLC raised its stake in shares of Stryker by 2.0% in the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after buying an additional 28 shares during the period. Finally, JFS Wealth Advisors LLC raised its stake in shares of Stryker by 4.4% in the fourth quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock worth $247,000 after buying an additional 29 shares during the period. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

NYSE:SYK traded up $0.51 during mid-day trading on Wednesday, reaching $382.86. The stock had a trading volume of 1,993,145 shares, compared to its average volume of 1,339,482. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker has a one year low of $314.93 and a one year high of $406.19. The firm has a 50 day moving average price of $368.77 and a two-hundred day moving average price of $376.09. The stock has a market capitalization of $146.13 billion, a P/E ratio of 49.34, a P/E/G ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $2.50 earnings per share. The business's revenue was up 11.9% on a year-over-year basis. As a group, analysts expect that Stryker will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.